VistaGen Therapeutics (NASDAQ: VTGN) Featured Research Report

6 A EGIS C APITAL C ORP. PH94B Neuroactive nasal spray VistaGen’s clinical-stage neuroactive nasal spray, PH94B, is designed to engage nasal chemosensory neurons with microgram doses of 3b-androsta-4,16-dien-3-ol. It is believed that in mammals, the hypothalamic-limbic areas of the brain receive direct afferent neural inputs from peripheral nasal chemosensory neurons, and that sensory transduction of external chemical cues in olfactory neurons triggers sensory inputs that reach the hypothalamus and the limbic amygdala through an oligosynaptic neural path. Administration of PH94B has been shown to induce heart rate decreases, and lower respiratory rate, electrodermal activity frequency, and eye blink frequency. 8 Fig. 2. Example of PH94B administration Fig. 3. Olfactory pathway Source: Brain wiki Source: VistaGen Therapeutics VistaGen Therapeutics, Inc. October 8, 2020